Data gathered: December 10
AI Stock Analysis - Moderna (MRNA)
Analysis generated October 20, 2024. Powered by Chat GPT.
Moderna, Inc. is a biotechnology company that rose to prominence with the development of its mRNA-based COVID-19 vaccine. Founded in 2010, Moderna specializes in drug discovery, drug development, and vaccine technologies based on messenger RNA (mRNA). The company has various other products in its pipeline, aimed at addressing infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. Moderna has become a household name due to the global pandemic and its efforts in combatting COVID-19, boosting its profile and investor interest.
Stock Alerts - Moderna (MRNA)
 |
Moderna | December 10 Price is down by -5.8% in the last 24h. |
|
Moderna | December 9 Price is up by 6.2% in the last 24h. |
|
Moderna | December 6 Price is up by 5.5% in the last 24h. |
|
Moderna | December 5 Price is up by 6.2% in the last 24h. |
Alternative Data for Moderna
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 192 | Sign up | Sign up | Sign up |
| Sentiment | 80 | Sign up | Sign up | Sign up |
| Webpage traffic | 307,000 | Sign up | Sign up | Sign up |
| Employee Rating | 70 | Sign up | Sign up | Sign up |
| Google Trends | 53 | Sign up | Sign up | Sign up |
| Patents | 228 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 67 | Sign up | Sign up | Sign up |
| Facebook Followers | 26,211 | Sign up | Sign up | Sign up |
| Reddit Mentions | 22 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 54 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 106,304 | Sign up | Sign up | Sign up |
| Twitter Followers | 146,895 | Sign up | Sign up | Sign up |
| Twitter Mentions | 182 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 11,900 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 80 | Sign up | Sign up | Sign up |
| Lobbying Cost | $3,000 | Sign up | Sign up | Sign up |
| Business Outlook | 50 | Sign up | Sign up | Sign up |
| Linkedin Employees | 7,031 | Sign up | Sign up | Sign up |
About Moderna
Moderna is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. It focuses on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA. Moderna's technology platform inserts synthetic nucleoside-modified mRNA into human cells.
| Price | $41.51 |
| Target Price | Sign up |
| Volume | 8,800,000 |
| Market Cap | $17.1B |
| Year Range | $36.85 - $166.61 |
| Dividend Yield | 0% |
| PE Ratio | 24.73 |
| Analyst Rating | 30% buy |
| Industry | Drug Manufacturers |
In the news
 |
Benjamin Edwards Inc. Has $292,000 Stock Position in Moderna, Inc. (NASDAQ:MRNA)December 10 - ETF Daily News |
Moderna Inc. stock outperforms competitors on strong trading dayDecember 9 - MarketWatch |
|
|
Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Public Sector Pension Investment BoardDecember 8 - ETF Daily News |
|
Townsquare Capital LLC Boosts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)December 6 - ETF Daily News |
|
Quantbot Technologies LP Invests $150,000 in Moderna, Inc. (NASDAQ:MRNA)December 6 - ETF Daily News |
|
Cerity Partners LLC Increases Stock Position in Moderna, Inc. (NASDAQ:MRNA)December 6 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 1.85B | 795M | 1.06B | 13M | -18M | 0.000 |
| Q2 '24 | 219M | 383M | -164M | -1.28B | -1.32B | -3.330 |
| Q1 '24 | 167M | 406M | -239M | -1.18B | -1.23B | -3.070 |
| Q4 '23 | 2.75B | 2.31B | 449M | 217M | 708M | 0.550 |
| Q3 '23 | 1.8B | 2.68B | -885M | -3.63B | -1.76B | -9.530 |
Insider Transactions View All
| Hoge Stephen filed to sell 1,443,904 shares at $43.3. December 4 '24 |
| Klinger Shannon Thyme filed to sell 19,837 shares at $43.3. December 4 '24 |
| Hoge Stephen filed to sell 1,443,567 shares at $42.8. December 2 '24 |
| Klinger Shannon Thyme filed to sell 19,717 shares at $42.8. December 2 '24 |
| Mock James M filed to sell 11,066 shares at $42.8. December 2 '24 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$149.23 0.2% | 46 |
 |
Eli Lilly and CompanyLLY |
$799.58 0.5% | 59 |
 |
PfizerPFE |
$25.57 2% | 35 |
 |
AstrazenecaAZN |
$67.18 2% | 61 |
 |
AbbVieABBV |
$175.67 0.5% | 56 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Ro Khanna |
Oct 8, 24 | Buy | $1K - $15K |
| Rohit Khanna Democrat |
May 6, 24 | Buy | $1K - $15K |
| Rohit Khanna Democrat |
Apr 5, 24 | Sell | $1K - $15K |
Read more about Moderna (MRNA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Moderna?
The Market Cap of Moderna is $17.1B.
What is Moderna's PE Ratio?
As of today, Moderna's PE (Price to Earnings) ratio is 24.73.
What is the current stock price of Moderna?
Currently, the price of one share of Moderna stock is $41.51.
How can I analyze the MRNA stock price chart for investment decisions?
The MRNA stock price chart above provides a comprehensive visual representation of Moderna's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Moderna shares. Our platform offers an up-to-date MRNA stock price chart, along with technical data analysis and alternative data insights.
Does MRNA offer dividends to its shareholders?
As of our latest update, Moderna (MRNA) does not offer dividends to its shareholders. Investors interested in Moderna should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Moderna?
Some of the similar stocks of Moderna are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.